Search research articles
Contact Us
Filters
Showing results (401-410 of 426) with videos related to
Page
of 43
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Adam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Elife
|
August 23, 2017
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
Laura Cato, Antje Neeb, Adam Sharp, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
The New England Journal of Medicine
|
December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapy
Charles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Cancer Discovery
|
January 12, 2021
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Jonathan Welti, Adam Sharp, Nigel Brooks, et al.
The Journal of Experimental Medicine
|
March 29, 2020
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
Ivana Hermanova, Patricia Zúñiga-García, Alfredo Caro-Maldonado, et al.
European Urology
|
November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
European Urology Oncology
|
June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
Pasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2025
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Jonathan Welti, Denisa Bogdan, Ines Figueiredo, et al.
Page
of 43
Search research articles
Search
Showing results (401-410 of 426) with videos related to
Sort By:
Page
of 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
Adam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
The Lancet. Oncology
|
December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Elife
|
August 23, 2017
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer
Laura Cato, Antje Neeb, Adam Sharp, et al.
Cancer Discovery
|
June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers
Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
The New England Journal of Medicine
|
December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapy
Charles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Cancer Discovery
|
January 12, 2021
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Jonathan Welti, Adam Sharp, Nigel Brooks, et al.
The Journal of Experimental Medicine
|
March 29, 2020
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
Ivana Hermanova, Patricia Zúñiga-García, Alfredo Caro-Maldonado, et al.
European Urology
|
November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
European Urology Oncology
|
June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
Pasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2025
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Jonathan Welti, Denisa Bogdan, Ines Figueiredo, et al.
Page
of 43